The purpose of this protocol is to determine the effects of testosterone administration and exercise to increase lean body mass and exercise functional capacity in eugonadal men with the AIDS wasting syndrome. The protocol is designed as a 3 month double blind, placebo controlled, randomized trial. All participants will be randomized to one of four arms: 1) testosterone plus excercise, 2) placebo plus exercise, 3) testosterone alone, and 4) placebo alone. 100 patients will be recruited for this study from the MGH ID clinic, other Infectious Disease units, primary care providers, social service agencies, posters, and advertisements. To be eligible, patients must be HIV positive, between the ages of 18 and 50 years old, and weigh less than 90% ideal body weight and/or have had involuntary weight loss of 10% of their pre-illness weight. Patients are excluded from the protocol for the following: new opportunistic infection within 6 weeks of starting the study; hemoglobin less than 9g/dL and/or platelets less than 50,000mm3; use of new antiretroviral within 8 weeks of baseline; active substance abuse; current use of hormones, steroids, ketoconazole, or parenteral nutrition; past medical history of cardiac disease; prostate malignancy, bipolar illness, hypothalamic or pituitary disease. Potential participants will have a screening visit on the GCRC in order to determine eligibility after informed consent is obtained. In addition to a history and physical exam, blood will be drawn for testosterone, complete blood count, and creatinine. If a patient's testosterone level is normal and he meets the previously mentioned criteria, he will be admitted to the GCRC for a 4 day inpatient stay, which will include evaluation of: hormonal status, including overnight growth hormone sampling and arginine stimulation; immune function as determined by CD4 count and viral load; body composition as determined by K40 isotope analysis, DXA, CT scan, bioimpedience analysis, and urine collections for creatinine excretion; nutritional status by evaluation of food record, metabolic rate, and inpatient calorie counts; exercise functional capacity and muscle function testing by physical therapy; and quality of life through multiple questionaires. Patietns return for a brief outpatietn visit at 6 weeks, and then repeat the inpatietn stay at the end of the study. Patietns will be randomized to receive either 200 mg testosterone enanthate IM or placebo every week. The patient has the option to either receive the injection on the GCRC or self-inject after careful instruction from nursing staff. Patients who are randomized to exercise will attend an exercise call three times a week at the Charles River Park fitness club that is led by MGH physical therapists who have worked on our previous AIDS studies. The exercise class will consist of aerobic conditioning and resistance training, in addition to warm up and cool down periods. In all cases, the patient's primary care provider will be contacted prior to enrollment to insure there are no specific contraindications to exercise. The primary endpoint for the study is change in fat-free mass as determined by DXA. Secondary endpoints include muscle strength and functionality as assessed by muscle function testing, body cell mass determined by K40 isotope analysis, muscle area as determined by CT scan, muscle mass per urinary creatinine excretion, and changes in quality of life as described by the questionnaires. If the patient chooses not to participate in this study they will receive standard medical care for their condition as prescribed by their physician.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
3M01RR001066-22S3
Application #
6220192
Study Section
Project Start
1998-12-01
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Fourman, Lindsay T; Czerwonka, Natalia; Shaikh, Sofia D et al. (2018) Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV. AIDS 32:927-932
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Arslanian, Silva; El Ghormli, Laure; Kim, Joon Young et al. (2018) The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in ?-Cell Function in TODAY. Diabetes Care :
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Foldyna, Borek; Fourman, Lindsay T; Lu, Michael T et al. (2018) Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr 78:421-428
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Srinivasa, Suman; Lu, Michael T; Fitch, Kathleen V et al. (2018) Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther 23:1-9

Showing the most recent 10 out of 945 publications